Keros halts blood pressure treatment trial on safety issues

Reuters

Jan 15, 2025

UPDATE 1-Keros halts blood pressure treatment trial on safety issues

Adds share movement in paragraph 2, disease background in paragraph 3, trial details in paragraphs 4-5

Jan 15 (Reuters) - Keros Therapeutics KROS.O said on Wednesday it would voluntarily halt testing of its experimental blood pressure treatment due to safety concerns during a mid-stage trial.

Its shares fell 8% to $11.52 in premarket trading.

The company was testing the therapy, cibotercept, in patients with pulmonary arterial hypertension — a rare, progressive lung disease that causes high blood pressure in the pulmonary arteries.

Keros said it observed excess fluid build up around the heart in patients. It is terminating the trial early and will monitor patients who were part of the study.

The company expects to present clinical data from the trial in the second quarter of 2025.

(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503061472"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503061472\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2503061472?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-15 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503061472","market":"us","top_or_hot":-1,"title":"Keros halts blood pressure treatment trial on safety issues","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-Keros halts blood pressure treatment trial on safety issues</title></head><body><p>Adds share movement in paragraph 2, disease background in paragraph 3, trial details in paragraphs 4-5</p><p><span>Jan 15 (Reuters)</span><span> - </span>Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>KROS.O</span> said on Wednesday it would voluntarily halt testing of its experimental blood pressure treatment due to safety concerns during a mid-stage trial.</p><p>Its shares fell 8% to $11.52 in premarket trading. </p><p>The company was testing the therapy, cibotercept, in patients with pulmonary arterial hypertension — a rare, progressive lung disease that causes high blood pressure in the pulmonary arteries.</p><p>Keros said it observed excess fluid build up around the heart in patients. It is terminating the trial early and will monitor patients who were part of the study.</p><p>The company expects to present clinical data from the trial in the second quarter of 2025.</p><p> (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)</p><p> ((Christy.Santhosh@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keros halts blood pressure treatment trial on safety issues</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeros halts blood pressure treatment trial on safety issues\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-15 19:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>UPDATE 1-Keros halts blood pressure treatment trial on safety issues</title></head><body><p>Adds share movement in paragraph 2, disease background in paragraph 3, trial details in paragraphs 4-5</p><p><span>Jan 15 (Reuters)</span><span> - </span>Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>KROS.O</span> said on Wednesday it would voluntarily halt testing of its experimental blood pressure treatment due to safety concerns during a mid-stage trial.</p><p>Its shares fell 8% to $11.52 in premarket trading. </p><p>The company was testing the therapy, cibotercept, in patients with pulmonary arterial hypertension — a rare, progressive lung disease that causes high blood pressure in the pulmonary arteries.</p><p>Keros said it observed excess fluid build up around the heart in patients. It is terminating the trial early and will monitor patients who were part of the study.</p><p>The company expects to present clinical data from the trial in the second quarter of 2025.</p><p> (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)</p><p> ((Christy.Santhosh@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KROS","symbol_name":"Keros Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nL4N3OB0W3:1","article_id":"2503061472","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503061472","pubTimestamp":1736942082,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UPDATE 1-Keros halts blood pressure treatment trial on safety issuesAdds share movement in paragraph 2, disease background in paragraph 3, trial details in paragraphs 4-5Jan 15  - Keros Therapeutics KROS.O said on Wednesday it would voluntarily halt testing of its experimental blood pressure treatment due to safety concerns during a mid-stage trial.Its shares fell 8% to $11.52 in premarket trading. The company was testing the therapy, cibotercept, in patients with pulmonary arterial hypertension — a rare, progressive lung disease that causes high blood pressure in the pulmonary arteries.Keros said it observed excess fluid build up around the heart in patients. It is terminating the trial early and will monitor patients who were part of the study.The company expects to present clinical data from the trial in the second quarter of 2025.  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KROS":"Keros Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Keros因安全问题停止血压治疗试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KROS":0.9},"content_text":"UPDATE 1-Keros halts blood pressure treatment trial on safety issuesAdds share movement in paragraph 2, disease background in paragraph 3, trial details in paragraphs 4-5Jan 15 (Reuters) - Keros Therapeutics KROS.O said on Wednesday it would voluntarily halt testing of its experimental blood pressure treatment due to safety concerns during a mid-stage trial.Its shares fell 8% to $11.52 in premarket trading. The company was testing the therapy, cibotercept, in patients with pulmonary arterial hypertension — a rare, progressive lung disease that causes high blood pressure in the pulmonary arteries.Keros said it observed excess fluid build up around the heart in patients. It is terminating the trial early and will monitor patients who were part of the study.The company expects to present clinical data from the trial in the second quarter of 2025. (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar) ((Christy.Santhosh@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}